A study has provided new insights into how psychedelics promote plasticity in the brain – suggesting that the antidepressant effects and the hallucinatory effects may have...
Algernon NeuroScience (AGN Neuro) has announced that its Phase 1 DMT trial is complete.
A study has been launched that is investigating COMP360 psilocybin therapy – an investigational new therapy – for treatment-resistant depression (TRD).
New data released by Sunstone Therapies shows positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive disorder (MDD).
In a groundbreaking milestone for psychedelics in Europe, a cross-party MEP Action Group for the Medical Use of Psychedelics was launched at an expert roundtable on...
MP Crispin Blunt raised a point of order in the House of Commons after the UK’s Drugs Minister failed to show up for a debate on...
Cybin Inc.
Two new drug candidates have been developed for the treatment of addiction and depression that have been modelled on the pharmacology of a traditional African psychoactive...
The use of psychedelics in research has a long and storied history, dating back to the mid-20th century.
With psilocybin showing promise for treating conditions such as depression and addiction, a team of scientists from the University of Southern Denmark has set out to...
